June 16, 2026 —
AviadoBio and King’s College London announced an expanded license agreement granting AviadoBio exclusive rights to apply the vMiX™ RNAi gene silencing platform across all human therapeutic areas.
The expanded agreement builds on the companies’ 2020 license, which gave AviadoBio rights to apply the platform to its gene therapy pipeline in neurological diseases. The new agreement broadens potential applications beyond the central nervous system, including cardiovascular disease, nephrology, oncology, and other therapeutic areas.
vMiX is a vectorized RNA interference platform designed to enable targeted and durable gene silencing using AAV delivery. By leveraging the natural cellular RNAi pathway, the platform is intended to reduce disease-causing gene expression after a single administration. Unlike non-vectorized RNAi approaches that may require repeat dosing, vMiX is designed for sustained suppression through AAV-mediated delivery.
A key feature of the platform is its flexibility. vMiX has the potential to silence up to three genes simultaneously and can also support “silencing and replacement” strategies through inclusion of a transgene sequence within the construct. Silencing activity can be controlled through tissue- or cell-specific promoters, allowing expression to be directed to regions of disease pathology.
The expanded license follows recent preclinical data for AVB-406, AviadoBio’s lead vMiX-enabled program for Alzheimer’s disease and other tauopathies. Data presented at the 2026 American Society of Gene & Cell Therapy Annual Meeting showed dose-dependent MAPT knockdown of up to 80% in the brain, supporting the platform’s potential for one-time, durable gene silencing.
AviadoBio said the broader license will allow the company to pursue strategic collaborations and partnerships in areas outside its core neuroscience focus. The company has been optimizing the vMiX platform since 2020 and has developed a discovery workflow that integrates in silico, in vitro, and in vivo design and selection to accelerate candidate identification and development.
The platform expansion reflects growing interest in AAV-delivered RNAi technologies as a genetic medicine modality. By combining durable knockdown, cell-specific expression, multi-gene targeting, and potential knockdown-and-replace functionality, vMiX may support new therapeutic strategies for diseases where reducing toxic or disease-driving gene expression is central to treatment.
AviadoBio remains focused on advancing its neuroscience pipeline, including programs in frontotemporal dementia with GRN mutations, retinitis pigmentosa and other retinal dystrophies, Alzheimer’s disease, and other tauopathies. The expanded license broadens the company’s ability to apply its platform beyond neurodegeneration while maintaining its core focus on precision AAV gene therapies.
